[ad_1]
The newly published data show that the COVID-19 vaccine developed by the University of Oxford and AstraZeneca is highly effective in preventing the virus. In light of this morning’s news, Prince William participated in a video call with the Oxford researchers, congratulating them on their success.
The call was attended by Professor Andy Pollard, Professor of Infection and Pediatric Immunity, Professor Sarah Gilbert, Professor of Vaccinology and Professor Louise Richardson, Vice Chancellor of the University of Oxford. The Duke of Cambridge heard about the group’s work against the coronavirus pandemic and expressed his gratitude for their commitment.
“Well done, I’m so happy for you all, I really am,” said the Duke. “I saw it on everyone’s faces in June how much time and effort they were putting into it, and I could see that there was a lot of pressure on everyone, so I’m so excited you fixed it, so really well done.”
Prince William refers to his June visit to the Oxford Vaccine Group at Churchill Hospital. There, he saw firsthand the efforts being made to create the vaccine and spoke highly of the “incredibly exciting and fascinating” work being done in the hospital.
That research has really paid off. AstraZeneca announced that provisional data from this new vaccine suggests 70% protection, but the percentage could reach 90% after changing the dose. This discrepancy arises from the 62% efficacy rates in the first trial group, which received two full doses of the vaccine, but from the 90% efficacy rates in the second group, which received a first half dose and a second full dose. . The two groups have an average efficacy of 70%, but none in either group developed severe COVID symptoms or needed hospitalization.
The announcement of the Oxford / AstraZeneca vaccine comes after both Pfizer and Moderna have produced vaccines that offer 95% protection from COVID-19. The crucial part of the Oxford vaccine, however, is its accessibility – this vaccine is both cheaper and easier to store than all the others. These features will make it easier for low-income countries to distribute the vaccine, along with rich countries.
“This vaccine should do what we’ve always wanted it to do. We wanted a vaccine for the world, not just for high-income countries, not just for this country,” Gilbert noted. “We’re not safe until we’re all safe.”
This content is created and maintained by a third party and imported on this page to help users provide their email addresses. You may be able to find more information on this and similar content on piano.io
Source link
